Emergent appoints Harsanyi, Katkin in board restructuring
Plus Sosei ratifies executive changes and updates from Mesoblast, Creyon and more
A week before Emergent BioSolutions Inc. (NYSE:EBS) founder and Executive Chairman Fuad El-Hibri was scheduled to retire on April 1, the company announced that he would be staying on as a consultant until March 2024 and that his executive chairman role was being eliminated. The company appointed Zsolt Harsanyi as an independent non-executive chairman, effective April 1; and Keith Katkin as an independent director. Harsanyi has served as a director of Emergent since August 2004, a director of Aptevo Therapeutics Inc. (NASDAQ:APVO) since August 2016, and chairman of the board of N-Gene Research Laboratories Inc. since March 2011. Katkin was CEO and board member at Urovant Sciences Ltd. from 2017 until 2020, and president and CEO of Avanir Pharmaceuticals Inc. from 2007 until 2016.
Katkin will be presented for election by the company’s stockholders at its 2022 Annual Meeting. If elected, he will assume the class 1 member role on the board vacated by El-Hibri, and serve on its nominating and corporate governance, and strategic operations committees. ...